Anti-mycobacterium tuberculosis vaccine using sendai virus as vector
AssigneesShanghai Public Health Clinical Center, Fudan University, ID Pharma Co., Ltd.
InventorsXiao-Yong Fan, Tsugumine Shu, Zhi-Dong Hu, Douglas B. Lowrie
Life of this patent
Estimating the term…
Abstract
Provided in the present application are a recombinant sendai virus vector vaccine expressing immunodominant antigens of mycobacterium tuberculosis, and can be used as therapeutic and preventive antituberculosis vaccine.
Claims11
A Sendai virus vector vaccine, wherein said vector expresses a mycobacterium tuberculosis immunogenic antigen.
A method of inducing a specific cellular immune response against a mycobacterium tuberculosis protein in vitro comprising:
- (a) introducing a Sendai virus vector that expresses a mycobacterium tuberculosis associated protein in a fusion into an antigen presenting cell;
- (b) contacting the antigen presenting cell with a cytotoxic T lymphocyte, wherein the mycobacterium tuberculosis protein comprises a protein selected from Ag85A, Ag85B, a fragment thereof, or any combination of any of the foregoing.
A recombinant Sendai virus vector, which is deposited at China Center for Type Culture Collection, under the accession number CCTCC V201518.
Dependencies are inferred from the claim text.